Accelerating Neuroscience Drug Development With First-in-Class circRNA Biomarkers
Circular Genomics is pioneering the use of brain-enriched circRNAs as highly stable, predictive, and scalable blood-based biomarkers for brain health disorders. Our platform enables earlier detection, progression prediction, and patient stratification to improve trial efficiency and increase the probability of success.
Why CircRNAs?
CircRNAs offer unique advantages for CNS biomarker development:
​
-
Highly stable and abundant in the brain
-
Detectable in blood with strong CNS pathway specificity
-
Provide biological insight not captured by traditional protein or linear RNA markers
1
Early Detection
& Patient Stratification in Alzheimer's Disease (AD)
Identify at-risk and fast-progressing patients earlier than conventional biomarkers.
Our validated circRNA signatures detect early biological changes and stratify patients by progression risk, improving screen-fail rates and enabling more efficient enrollment.
Use Cases​​
-
Preclinical AD risk assessment
-
Progression prediction
-
Funnel optimization to reduce PET burden
2
Clinical Trial Enrichment & Monitoring
Increase statistical power and reduce sample size & trial variability.
circRNA-based profiles support patient selection, responder prediction, and early biological response monitoring, driving stronger signal detection in Phase 1–3.
Use Cases​​
-
Patient enrichment based on biology
-
Early go/no-go decision support
-
Longitudinal disease progression and treatment-response tracking
3
Mechanistic & Pathway Insights
Deep biological understanding of CNS disease heterogeneity.
Our validated circRNA signatures detect early biological changes and stratify patients by progression risk, improving screen-fail rates and enabling more efficient enrollment.
Use Cases​​
-
MOA and target pathway insights
-
Cohort characterization
-
Biomarker-driven CDx co-development
